PTGX — Stock Film
STOCK FILMSCENE 1/11PTGX · $122
Stock Expert AI presents
PTGX
Protagonist Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Protagonist Therapeutics, Inc. A quick introduction.

On the stock market since 2016, it operates in the world of health and science. It has 124 employees. Now — the numbers.

on the stock market since 2016
124 employees
$7.8B market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $4.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
Sales are growing overall, with a pause along the way.

Average growth of 14% a year over the last 4 years. Red columns mark years that ended in a loss.

$27.4M
2021
$26.6M
2022
$60M
2023
$434.4M
2024
$46M
2025
In the vault right now:
$0
DEBT: $10.3M
At this pace, that money lasts about 4.4 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
37
weak

Clearly below the class average.

FINANCIAL STRENGTH
74
strong

Clearly above the class average — a step short of the very top.

VALUATION
50
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
4
very weak

Clearly below the class average.

PRICE MOMENTUM
92
very strong

The stock has been running stronger than the market lately.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
Executives aren’t buying3/10
Costs eat into the margin4/10
WORTH WATCHING

Executive Buying: The trades send no strong signal of confidence.

THE FIVE-YEAR JOURNEY
Trading below its recent peak.

The stock trades below its recent peak — about 14% off the top. A pullback, not a collapse.

1
THE BRIGHT SIDE · 1/2
The product is selling

Sales run at $46.0M a year. A small number, but proof the product has real buyers.

2
THE BRIGHT SIDE · 2/2
Strong cash, light debt

There is $567.4M in the vault; even if every debt were paid off, $557.0M would remain.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $130.1M against $46.0M in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
Growth trails the sector

The growth engine is running at low revs right now. Report-card grade: 4/100.

3
THE RISKS · 3/3
The business trails its class

Measured against its sector, the quality of the business sits below the class average. Report-card grade: 37/100.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, PTGX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: PTGX is a high-risk stock — not yet profitable, and its future rides on its product catching on.

The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 21, 2026 · stockexpertai.com · Stock Film